Multifactorial analysis suggested that patients with late TNM staging (HR: 14.957, 95% CI: 1.849–120.956, P < 0.05), CEA > 5 ng/ml, and mSEPT9-positive patients (HR: 5.321, 95% CI: 1.702–16.636, P < 0.05) had a worse prognosis, which was an independent predictive risk factor for CRC patients (Table 3). The gene discussed is CEACAM5; the disease is colorectal carcinoma.